Stem Cell Therapy for Back Pain and Disc Disease

Short answer: In our reading, stem cell injections for back pain are mostly studied in one condition, degenerative disc disease, where a disc between the vertebrae has worn down and may cause pain. The largest sham-controlled trial we found showed no significant difference between stem cells and a sham injection. We found no reliable published Bangkok price for this treatment. According to a lawsuit reported by Nation Thailand in December 2024, the Medical Council warned at an October 31 press conference that treating conditions outside blood or eye diseases with stem cells could be unlawful.

This guide is general information for someone weighing a trip. It describes what published studies measured. It does not say what any treatment will do for you.

What the procedure is

In the trials we cite, the treatment is a single injection of mesenchymal stem cells directly into the affected disc. In the RESPINE trial, the dose was 20 million donor (allogeneic) bone marrow cells. In a 2017 trial, donor bone marrow cells were injected into each disc segment under local anesthesia. Other studies use biologic injections such as platelet-rich plasma (PRP). These are different products, and in our reading results for one do not carry over to another.

What the evidence shows, and what it does not

RESPINE, 2024. This multicentre trial in Annals of the Rheumatic Diseases enrolled 114 adults with chronic low back pain. Half were randomized to one intradiscal injection of 20 million donor bone marrow stem cells (58 people) and half to a sham injection (56 people), in a double-blind design. The main measure was the share of "responders," defined as at least a 20 percent and 20 mm improvement on a pain scale, or a 20 percent improvement on the Oswestry Disability Index, at 12 months. It was 74 percent in the stem cell group and 69 percent in the sham group (p = 0.77). The groups also did not differ on the secondary outcomes. The trial's second co-primary endpoint was disc fluid content on MRI. The authors wrote that the study "did not conclusively demonstrate the efficacy" of the cells.

Notice how many people in the sham group counted as responders. That is why a control group matters when judging a treatment for pain.

A smaller trial, 2017. Noriega and colleagues (Transplantation) randomized 24 people with chronic back pain from disc degeneration, who had not responded to conservative treatment, to donor bone marrow cells in the disc or to a sham injection of anesthetic into the back muscles. The authors reported a quick and significant improvement in the stem cell group, but said it seemed restricted to responders making up 40 percent of the cohort. Twenty-four people is a small sample.

Reviews. Schneider and colleagues (The Spine Journal, 2022) reviewed 12 studies of intradiscal biologics, including stem cells and PRP. They noted that the single trial of mesenchymal stem cells they found was negative. Not a success rate: pooling mostly observational data, they report that 53.5 percent of stem cell patients had at least 50 percent pain relief at 6 months, and in a worst-case analysis the figure fell to 40.7 percent, with the evidence rated very low quality.

Manchikanti and colleagues (Pain Physician, 2024) pooled randomized and observational studies. They concluded that intradiscal stem cell and PRP injections "may be effective" for discogenic back pain, supported by Level III evidence (which the review calls fair), and described a paucity of high-quality studies. We cannot tell from the abstract whether RESPINE was among the trials they pooled. Schneider rates the evidence very low quality and Manchikanti rates it fair with limited certainty; neither calls it strong.

How to read these numbers. The trials define "success" differently. RESPINE counted a responder as a 20 percent improvement on either a pain scale or a disability questionnaire. Schneider's review counted at least 50 percent pain relief at 6 months. A percentage from one study cannot be compared with a percentage from another. Studies without a control group cannot separate the effect of the cells from the effect of the injection itself, of time, or of expectation, which is why sham-controlled trials such as RESPINE and the 2017 trial are more informative.

What this means. Our reading, based on fewer randomized trials, is that the evidence is thinner than for knee osteoarthritis. The one large sham-controlled trial we found did not show a difference.

Established alternatives

The American College of Physicians' 2017 guideline (Annals of Internal Medicine) says that for chronic low back pain, people should initially choose nonpharmacologic treatment: exercise, multidisciplinary rehabilitation, acupuncture, mindfulness-based stress reduction, and several others it lists. If the response is inadequate, it says to consider NSAIDs first, then tramadol or duloxetine, and opioids only after those have failed. The guideline covers noninvasive treatment and does not address stem cells.

Who may be a poor candidate

The abstracts we reviewed do not name groups who should be excluded from intradiscal stem cell injections. Ask your own doctor first, especially if you have an active infection, a cancer history, a bleeding disorder, take blood thinners or are pregnant. These are our prompts, not exclusion rules from the cited studies. The trials enrolled adults with chronic low back pain, and the 2017 trial enrolled people who had not responded to conservative treatment. A doctor who has seen your imaging and history is the right person to ask, before you travel.

Risks

RESPINE reported no serious adverse event related to the intervention. Noriega and colleagues said feasibility and safety were confirmed in their 24 patients. Both are small groups, and the abstracts we reviewed give no long-term safety figures for this procedure.

An injection into a spinal disc is an invasive procedure. Ask the clinic in writing which complications it has seen and how they were treated.

The US FDA's public information on regenerative medicine therapies (3 June 2021) says it has received reports of blindness, tumor formation and infections linked to unapproved products. Those reports are not specific to back treatment.

Published Bangkok prices

We found no reliable published price for back or disc stem cell treatment. The two price pages we checked, Stemcierge (updated 19 September 2026) and Bookimed (its page showed "Last updated 11/03/2026" when we read it on 4 November 2026), list prices for knees, arthritis in general and other programs, but no figure for the spine that we could verify. The knee prices in our knee guide are for a different procedure and should not be assumed for the back. Our cost guide lists what is published and what drives the price. Ask any clinic for an itemized written quote.

Thai legal status

Back pain and disc degeneration are not blood or eye diseases. In December 2024, Nation Thailand reported a lawsuit by a group of doctors against the Medical Council of Thailand. The lawsuit, as Nation Thailand describes it, cites an October 31 press conference at which the Council warned that treating conditions outside of blood or eye diseases with stem cells could be unlawful.

Nation Thailand also reported, on 27 May 2026, a ministerial decree that classifies cell products with "more than minimal manipulation," such as cells expanded in culture or enzymatically digested, as medicines that need registration with the Thai FDA. This guide is not legal advice. Our guide Is stem cell therapy legal in Thailand? has the full set of facts and sources.

Five questions to ask a clinic

• Is this treatment part of a regulated clinical trial with ethics committee approval, or is it offered outside one?
• Is the cell product registered with the Thai FDA, and for which condition?
• What is the source of the cells, how many are in the dose, and are they only cut, spun or separated, or cultured, enzyme-treated or otherwise processed further?
• What published studies support injecting this product into a disc, and what did they measure?
• What is included in the price, and who pays and where do I get care if I have a complication after I fly home?